340B PATIENTS Act of 2025
- Sponsor
- Rep. Matsui, Doris O. [D-CA-7]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jul 22, 2025
Bottom line
The bill aims to protect and expand access to discounted drugs for vulnerable patients by preventing drug manufacturers from restricting the 340B program's use, particularly regarding contract pharmacies, and by imposing penalties for non-compliance.
What it actually does
This bill clarifies and strengthens the requirements for drug manufacturers participating in the 340B drug discount program, explicitly prohibiting them from placing conditions on covered entities' ability to purchase and use discounted drugs, regardless of the dispensing method or location. It specifically affirms the legality of contract pharmacy arrangements and establishes significant civil monetary penalties for manufacturers who violate these provisions.
Proponents argue
Supporters argue the bill restores Congress's original intent for the 340B program, ensuring covered entities can continue to 'stretch scarce resources' to serve more patients and provide comprehensive services, especially for specialty drugs. They contend it prevents manufacturers from unilaterally undermining the program's purpose and the vital savings it generates for community health.
Opponents contend
Drug manufacturers would likely argue that the current system, particularly with contract pharmacies, leads to diversion and abuse of 340B discounts, allowing entities to profit rather than directly benefiting vulnerable patients. They might contend the bill removes necessary safeguards and could lead to higher drug costs for other payers by expanding what they perceive as program loopholes.
The bill is concise and clearly written, allowing for a quick and thorough understanding of its core objectives and mechanisms.
Section 3(a)(1)
Prohibiting Conditions on 340B Drug Purchases and Use
This provision amends Section 340B(a)(1) of the Public Health Service Act to explicitly state that drug manufacturers must offer discounted prices regardless of how or where the drug is dispensed. It prohibits manufacturers from imposing conditions on covered entities' ability to purchase and use these drugs, such as limits on delivery, purchase mechanisms, dispensing locations, or requirements for claims data submission, unless such conditions are approved by the Secretary of Health and Human Services.
Supporters argue
Supporters argue this clarification is essential to prevent manufacturers from unilaterally undermining the 340B program through restrictive conditions, which they contend is contrary to congressional intent and harms covered entities' ability to serve vulnerable patients.
Critics contend
Drug manufacturers would likely argue that these conditions are necessary to prevent diversion of discounted drugs to ineligible patients or to ensure program integrity, and that removing them could lead to abuse and increased costs for the broader healthcare system.
Tradeoffs
The tension is between ensuring broad access to discounted drugs for covered entities to support patient care and manufacturers' concerns about program oversight and potential misuse of discounts.
Section 3(a)(2)
Explicit Inclusion of Contract Pharmacies in 340B Protections
This provision adds a new paragraph (11) to Section 340B(a), explicitly stating that the requirements and prohibitions on manufacturers (including the new ones from paragraph (1)) apply when a covered entity uses one or more contract pharmacies to dispense discounted drugs to its patients. This legally affirms the ability of covered entities to use contract pharmacy arrangements within the 340B program.
Section 3(b)(1)
Imposing Civil Monetary Penalties for Manufacturer Non-Compliance
This section amends 340B(d)(1)(B) to introduce new civil monetary penalties for manufacturers who violate the prohibitions on placing conditions (subsection (a)(1)(C)) or interfering with contract pharmacies (subsection (a)(11)), other than overcharging. These penalties can be up to $2,000,000 per day per violation, determined by the Secretary based on factors like the nature, extent, and harm of the violation, and continue until the violation ceases.
Section 3(b)(2)
Establishing a Claims Process for Covered Entities to Assert Violations
This section mandates the Secretary of Health and Human Services to promulgate regulations within 180 days of enactment. These regulations will permit covered entities to assert claims of violations of manufacturer obligations under subsections (a)(1) and (a)(11) through an established dispute resolution process. This provides a formal, regulated mechanism for covered entities to report and seek redress for manufacturer non-compliance.
Requires the Secretary of Health and Human Services to promulgate regulations within 180 days to allow 340B covered entities to assert claims of violations regarding manufacturer conditions on drug purchases and interference with contract pharmacy arrangements.
Section 3(b)(2), amending Section 340B(d)(3)
Why it matters:This is standard legislative practice for amending existing law by integrating new directives into established statutory frameworks.
Case for: Supporters argue this ensures covered entities have a formal, clear pathway to report non-compliance, which is crucial for the program's integrity and for holding manufacturers accountable for their obligations.
Case against: Manufacturers might argue that expanding the claims process could lead to an increase in administrative disputes, potentially diverting resources from patient care or drug development due to increased litigation and compliance costs.
Estimated impact: Creates a new regulatory framework and dispute resolution pathway for 340B violations, potentially increasing the number of formal complaints and enforcement actions against manufacturers.